转移性肾细胞癌转移灶切除术围手术期并发症的多中心国际特征分析
该回顾性队列研究纳入2005至2020年两家高容量中心的522例转移性肾细胞癌患者共740次转移灶切除术,26%发生30天并发症,8%发生重大并发症(Clavien-Dindo III-V级),包括1%围手术期死亡;重大并发症率低于既往基于人群数据,在高容量中心精选患者中可获良好围手术期结局。
要点
- 740次转移灶切除术中26%发生30天并发症,8%为重大并发症,1%围手术期死亡。
- 年龄、BMI、ASA评分、同期肾切除、多部位转移、胰腺切除及转移灶大小与并发症显著相关。
- 年龄、多部位转移和胰腺切除与重大并发症显著相关。
核心结论
- 在该多中心系列中,不到10%的转移性肾细胞癌转移灶切除术在术后30天内发生重大并发症,明显低于既往基于人群数据观察到的结果。
- 在高容量中心对经过良好选择的患者行转移灶切除术可获得良好的围手术期结局。
研究设计与样本
- 回顾性队列研究,纳入2005年至2020年在两家高容量中心接受转移性肾细胞癌转移灶切除术的患者。
- 共识别522例患者的740次转移灶切除术,其中梅奥诊所543次、鲁汶大学医院197次。
- 采用广义估计方程分析二分类反应,评估特征与按Clavien-Dindo分级分类的30天并发症的关联。
主要发现
- 740次转移灶切除术中,193次(26%,95%CI 23-29%)发生30天并发症,62次(8%,95%CI 7-11%)发生重大(Clavien-Dindo III-V级)并发症,包括8次(1%)围手术期死亡。
- 年龄、体重指数、美国麻醉医师协会评分、转移灶切除同期肾切除、多部位转移、胰腺切除及转移灶大小与术后并发症显著相关(均p<0.05)。
- 年龄、多部位转移和胰腺切除与重大(Clavien-Dindo III-V级)并发症显著相关(均p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括回顾性设计和手术选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical resection of metastatic renal cell carcinoma (mRCC) has been associated with better cancer-specific survival; however, high-quality data on its perioperative morbidity are lacking. Existing population-based data are severely limited by reliance on billing claims to identify outcomes, which may overestimate events owing to a lack of code specificity. OBJECTIVE: To study 30-d complications after metastasectomy for mRCC. DESIGN, SETTING, AND PARTICIPANTS: The study involved a retrospective cohort of patients who underwent metastasectomy for mRCC between 2005 and 2020 at two high-volume centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used generalized estimating equations for a binary response to evaluate associations of features with 30-d complications classified according to Clavien-Dindo grade. RESULTS AND LIMITATIONS: A total of 740 metastasectomies in 522 patients were identified, including 543 performed in the Mayo Clinic and 197 in UZ Leuven. Among the 740 metastasectomies, 193 (26%, 95% confidence interval [CI] 23-29%) had a 30-d complication and 62 (8%, 95% CI 7-11%) had a major (Clavien-Dindo III-V) complication, including eight (1%) perioperative deaths. Age, body mass index, American Society of Anesthesiologists score, metastasectomy concurrent with nephrectomy, multiple sites of metastasis, pancreatic resection, and metastasis size were significantly associated with postoperative complications (all p < 0.05). Age, multiple sites of metastasis, and pancreatic resection were significantly associated with major (Clavien-Dindo III-V) complications (all p < 0.05). Limitations include the retrospective design and surgical selection bias. CONCLUSIONS: In this multi-institutional series, fewer than 10% of metastasectomies for mRCC resulted in a major complication within 30 d of surgery, which is considerably lower than previously observed in population-based data. Favorable perioperative outcomes can be achieved with metastasectomy at high-volume centers in well-selected patients. PATIENT SUMMARY: In this study we found that fewer than 10% of patients who underwent surgical removal of one or more sites of metastatic kidney cancer experienced a major complication within 30 days of surgery.
引用
- Lyon TD, Roussel E, Sharma V, et al. International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma. Eur Urol Oncol. 2022. PMID: 36509653. doi:10.1016/j.euo.2022.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。